openPR Logo
Press release

Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions

09-24-2025 12:18 PM CET | Health & Medicine

Press release from: CSOFT International, Inc.

Sesen Launches with a Singular Mission: Advancing Life Sciences

Boston, MA - Today marks the official launch of Sesen, a next-generation language services company purpose-built to meet the complex demands of the life sciences industry. Specializing exclusively in translation, localization, and AI-enhanced linguistic solutions for pharmaceutical, biotechnology, medical device, CRO, and regulatory organizations, Sesen combines industry expertise with cutting-edge technology to deliver faster, more accurate, and fully compliant multilingual communications across 150+ languages.

Built by industry veterans, Sesen is redefining how global life sciences companies manage language workflows-from clinical trial documentation and regulatory labeling to patient communications and digital health platforms. At the core of its offering is SesenGPT, a proprietary AI engine trained on life sciences terminology and optimized for medical and regulatory content.

Key Capabilities Include:
Regulatory-compliant translations aligned with EMA, FDA, and PMDA guidelines
ISO 17100, ISO 9001:2015, and ISO 13485:2016 certified quality management
AI-enabled hybrid workflows for clinical trial translations, pharmacovigilance, and labeling
Native linguists and MD/PhD medical reviewers for domain-specific accuracy
Scalable language solutions integrated with sponsor CMS and eTMF systems
"Life sciences innovation is increasingly global, but language remains a critical barrier," said Dr. Vladimir Misik, VP of Global Clinical Trial Strategy at Sesen. "We launched Sesen to solve this challenge with unmatched specialization, seamless technology integration, and the linguistic precision this industry demands."

Diego Di Leva, Sesen's VP of Global Operations and Strategic Partnership, and a certified ISO 9001 and ISO 13485 auditor, added:

"At Sesen, language quality is not an afterthought-it's built into the DNA of every project. Our quality assurance framework is grounded in international standards and supported by linguists with deep domain expertise, ensuring every deliverable meets the highest regulatory and scientific expectations."

With a growing network of professional linguists, in-country reviewers, and regulatory consultants, Sesen is already supporting top-10 pharmaceutical and biotechnology companies with compliant, on-time delivery of multilingual assets for global product launches, international clinical trials, and worldwide regulatory submissions.

To learn more about Sesen or to request a quote, visit www.sesen.com.

Media Contact:
Nikki Andrews
press@sesen.com

1 Post Office Square, 23rd Floor, Suite 23200

Sesen is a specialized language solutions provider exclusively serving the life sciences industry. With a focus on clinical, regulatory, and commercial translation services, Sesen supports pharmaceutical, biotech, medical device, and CRO clients in over 150 languages. The company combines expert native linguists, medical professionals, and ISO-certified workflows with proprietary AI technology to deliver faster, more accurate, and fully compliant multilingual content. From global clinical trial support to in-market product localization, Sesen enables life sciences organizations to operate with linguistic confidence and regulatory precision worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions here

News-ID: 4194517 • Views:

More Releases for Sesen

BCG-unresponsive NMIBC market is projected to reach $4.1 billion by 2034
Bladder cancer is among the most common urologic malignancies worldwide, with non-muscle invasive bladder cancer (NMIBC) representing approximately 70-75% of all new cases. Standard first-line therapy involves transurethral resection followed by intravesical instillation of Bacillus Calmette-Guérin (BCG). While effective in many cases, a significant subset of patients becomes BCG-unresponsive, meaning their disease progresses or recurs despite adequate treatment. This presents a serious clinical challenge, as these patients are at high
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery
Non-Muscle Invasive Bladder Cancer Market: Epidemiology, Therapies, Companies, D …
Non-Muscle Invasive Bladder Cancer therapies are expected to boost the Non-Muscle Invasive Bladder Cancer Market in the upcoming years. DelveInsight has launched a new report on "Non-Muscle Invasive Bladder Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France,
Non-Muscle Invasive Bladder Cancer Pipeline Analysis (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Non-Muscle Invasive Bladder Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trial Analysis and NDA App …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including Non Muscle Invasive Bladder Cancer clinical trial and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration,
Investigation announced for Long-Term Investors in NASDAQ: SESN shares over poss …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors of Sesen Bio, Inc.. Investors who are current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: SESN stocks follows a lawsuit filed against Sesen Bio,